Comparative Pharmacology
Head-to-head clinical analysis: FERROUS FUMARATE versus FERUMOXYTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERROUS FUMARATE versus FERUMOXYTOL.
FERROUS FUMARATE vs FERUMOXYTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron is an essential component of hemoglobin, myoglobin, and various enzymes; ferrous fumarate provides elemental iron for erythropoiesis and oxygen transport.
Ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle that provides a source of iron for erythropoiesis. It is phagocytosed by macrophages of the reticuloendothelial system, and iron is released intracellularly to bind to transferrin and ferritin, replenishing iron stores.
Oral: 200 mg (equivalent to 65 mg elemental iron) three times daily. Adults: 325 mg (106 mg elemental iron) one to three times daily.
510 mg intravenously once, followed by 510 mg intravenously 3 to 8 days later for a total cumulative dose of 1020 mg. Administer as a slow IV injection at 1 mL/min (30 mg/min) undiluted or diluted in 50-200 mL normal saline.
None Documented
None Documented
5-7 hours for iron in serum after absorption; terminal half-life of storage iron (ferritin) is approximately 6 days; clinical context: follows first-order kinetics with iron recycling.
Terminal elimination half-life is approximately 14-21 hours in healthy adults; prolonged in patients with iron deficiency anemia (up to 30 hours) due to increased iron utilization.
Primarily fecal (about 90%) as unabsorbed iron; minor renal excretion (<1%) via sloughed intestinal cells and bile; negligible urinary elimination.
Ferumoxytol is eliminated primarily through the reticuloendothelial system, with the iron moiety incorporated into hemoglobin or stored as ferritin/hemosiderin. Minimal renal or biliary excretion of intact drug; <1% excreted unchanged in urine.
Category C
Category C
Iron Replacement
Iron Replacement